Pre-ERCP infusion of semapimod, a mitogen-activated protein kinases inhibitor, lowers post-ERCP hyperamylasemia but not pancreatitis incidence.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples